Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
The predictive genomics market is a rapidly growing sector, with Genetic Technologies Limited (GENE) positioning itself as a key player through its geneType multi-risk test. The test's ability to predict risks for multiple diseases, including some with high mortality rates, could potentially disrupt the market. By securing more than 50 risk assessment tests and a portfolio of patents, GENE is creating a competitive moat that may appeal to investors looking for companies with a strong intellectual property base and diversified offerings.
GENE's dual focus on B2B and direct-to-consumer models aligns with the trend of personalized medicine, tapping into a market expected to reach $4.6 billion by 2025. This strategic positioning could enable GENE to capture a significant market share, benefiting from economies of scale and potentially increasing its bargaining power with partners and suppliers.
BioVie Inc.'s (BIVI) development of NE3107 addresses a substantial market need in neurodegeneration, targeting Alzheimer's and Parkinson's diseases—areas with limited effective treatments. The positive trending data from the Phase 3 trial in Alzheimer's suggests potential for NE3107 as a therapeutic option, which could have a significant impact on BIVI's valuation and market position. The planned launch of Phase 3 trials in 2024 for multiple indications highlights the company's aggressive development pipeline.
BIV201's focus on refractory ascites and hepatorenal syndrome-acute kidney injury (HRS-AKI) represents a strategic move into niche markets with unmet medical needs, potentially allowing BioVie to capitalize on orphan drug status and pricing. The company's multi-front approach in drug development could mitigate risks and enhance investor confidence in its long-term growth prospects.
For both Genetic Technologies and BioVie, the strategic updates provided in the interviews could influence investor sentiment and stock performance. The growth projections for GENE's market and the positive trial results for BIVI's therapies are critical pieces of information that could affect their respective stock valuations. Investors will likely scrutinize the scalability of GENE's commercialization strategy and the regulatory paths for BIVI's therapies.
Long-term implications for stakeholders include the potential for revenue growth from new product launches and market expansion. However, the inherent risks of clinical trials and the regulatory landscape must be considered. Any setbacks could impact the companies' financial health and stock prices. Conversely, successful commercialization and favorable trial outcomes could lead to significant returns for investors.
12/29/2023 - 09:00 AM
ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
In an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. The Multi-Risk test, along with integration of recently acquired DNA based products, underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage. GENE's expanding product portfolio includes more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In addition to its B2B model, GENE is also focused on expanding its direct-to-consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17% +.
Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer's (AD) and Parkinson's (PD) and BIV201 for refractory ascites and HRS-AKI. BioVio recently reported data from a Phase 3 trial in AD that showed positive trending data showing that patients treated with NE3107 had treatment advantages compared to placebo on various cognitive, functional, and biomarker endpoints. The Company plans to launch Phase 3 trials in Alzheimer's, Parkinson's, and Ascites in 2024 and has multiple other efforts underway that may create additional catalysts.
About Genetic Technologies
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com .
About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company is conducting a Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/ .
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Small Stocks Big Money® Show is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Small Stocks Big Money® Show," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentryinfo@redchip.com
SOURCE: RedChip
press release on accesswire.com
What is the schedule for the interviews with Genetic Technologies Limited and BioVie, Inc. on Bloomberg TV?
The interviews will be aired on The RedChip Small Stocks Big Money® Show on Bloomberg TV on Saturday, December 30, at 7 p.m. Eastern Time (ET).
What is Genetic Technologies Limited's ticker symbol?
The ticker symbol for Genetic Technologies Limited is GENE.
What is BioVie, Inc.'s ticker symbol?
The ticker symbol for BioVie, Inc. is BIVI.
What is Genetic Technologies Limited's B2B commercialization strategy focused on?
Genetic Technologies Limited is focusing on its flagship geneType multi-risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease, and Type-2 diabetes, which can predict a person's risk in up to 70% of annual mortalities and morbidities before onset.
What is the global market expectation for predictive genomics by 2025?
The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+.
What is BioVie, Inc. developing transformative therapies for?
BioVie, Inc. is developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
